Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 51Small Cell Lung Carcinoma 23Lung Neoplasms 10NSCLC 5Non-squamous Non-small Cell Lung Cancer 3Neoplasms 3Carcinoma 3Extensive Stage Small Cell Lung Cancer 2Brain Neoplasms 2Adenocarcinoma of Lung 2Squamous Non-small Cell Lung Cancer 1Small Cell Lung Cancer Limited Stage 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1SCLC 1Non-squamous Non-small-cell Lung Cancer 1Non-squamous Cell Non-Small Cell Lung Cancer 1Non-Squamous Non Small Cell Lung Cancer 1Non Small Cell Lung Cancer Recurrent 1Neoplasm, Residual 1Neoplasm Metastasis 1Locally Advanced Non-small Cell Lung Cancer 1Limited Stage Small Cell Lung Cancer 1IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy 1Extensive Small Cell Lung Cancer 1Aumolertinib 1Advanced Non-small Cell Lung Cancer 1

Interventions

Etoposide 2Carboplatin 2anlotinib 1Radiotherapy 1Drug Therapy 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Small Cell Lung Cancer × anlotinib × Thoracic × Clear all
NCT04234607 2020-01-22

A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Unknown
738 enrolled
Thoracic

Extensive Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡